German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients

Journal of Nuclear Medicine

Volumn 58, Issue 1, 2017, Pages 85-90

  Rahbar, Kambiz ^a   Ahmadzadehfar, Hojjat ^b   Kratochwil, Clemens ^c   Haberkorn, Uwe ^c   Schafers, Michael ^a   Essler, Markus ^b   Baum, Richard P ^d   Kulkarni, Harshad R ^d   Schmidt, Matthias ^e   Drzezga, Alexander ^e   Bartenstein, Peter ^f   Pfestroff, Andreas ^g   Luster, Markus ^g   Lutzen, Ulf ^h   Marx, Marlies ^h   Prasad, Vikas ⁱ   Brenner, Winfried ⁱ   Heinzel, Alexander ^j   Mottaghy, Felix M ^j   Ruf, Juri ^k   Meyer, Philipp Tobias ^k   Heuschkel, Martin ^l   Eveslage, Maria ^m   Bögemann, Martin ^a   Fendler, Wolfgang Peter ^f   Krause, Bernd Joachim ^l,n   more..

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET CT) Zentralklinik Bad Berka   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m UNIVERSITY OF MÜNSTER   (Germany)

ⁿ German Society of Nuclear Medicine Göttingen   (Germany)

more..

Author keywords

MCRPC; Prostate cancer; PSMA 617; Radioligand therapy

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; LUTETIUM 177; LUTETIUM 177 PROSTATE SPECIFIC MEMBRANE ANTIGEN 617; PROSTATE SPECIFIC ANTIGEN; RADIOLIGAND; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; BLOOD TOXICITY; BONE METASTASIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FRACTURE; GERMAN (CITIZEN); HUMAN; ILEUS; KIDNEY FAILURE; LEUKOPENIA; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MEDICINE; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VERTIGO; VERY ELDERLY; VISCERAL METASTASIS; XEROSTOMIA; AGE DISTRIBUTION; CAUSALITY; CLINICAL TRIAL; COMORBIDITY; GERMANY; HEMATOLOGIC DISEASES; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; DIPEPTIDES; GERMANY; HEMATOLOGIC DISEASES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 85009062605     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.183194     Document Type: Article

References (25)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528-539.
4. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
5. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
6. Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1629-1630.
7. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
8. Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57:563-567.
9. Giesel FL, Sterzing F, Schlemmer HP, et al. Intra-individual comparison of ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1400-1406.
10. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. January 18, 2016 [Epub ahead of print].
11. Beněsová M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56: 914-920.
12. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study. EJNMMI Res. 2015;5:114.
13. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrateresistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488.
14. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57:1170-1176.
15. Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis. J Nucl Med. 2016;57:1334-1338.
16. Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522-528.
17. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castrationresistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-1418.
18. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028-1038.
19. Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: A multicentre analysis. Eur Urol. 2015;68:317-324.
20. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24:1802-1807.
21. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
22. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisolone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376:1147-1154.
23. Tagawa ST, Milowsky ML, Morris M, et al. Phase II study of lutetium-177-labeled anti prostate-specific antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
24. Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, Gernhardt CR, Kuhnt T. Parotid gland-recovery after radiotherapy in the head and neck region: 36 months follow-up of a prospective clinical study. Radiat Oncol. 2011;6:125.
25. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castrationresistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29:3695-3704.